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A B S T R A C T
Current pharmacological treatments for neuropathic pain have limited efficacy and severe side-effect
limitations. St. John’s Wort (SJW) is a medicinal plant, mainly used as antidepressant, with a favourable
side-effect profile. We here demonstrate the ability of SJW to relieve neuropathic pain in rat models. The
antihyperalgesic profile and mechanism of action of SJW and its main components were studied in two
rat models of neuropathic pain: the chronic constriction injury and the repeated administration of
oxaliplatin. SJW, acutely administered at low doses (30–60 mg kg1 p.o.), reversed mechanical
hyperalgesia with a prolonged effect, being effective up to 180 min after injection. Further examinations
of the SJW main components revealed that hyperforin and hypericin were responsible for the
antihyperalgesic properties whereas flavonoids were ineffective. The effect of SJW on the PKC expression
and activation was investigated in the periaqueductal grey (PAG) area by immunoblotting experiments.
Mechanistic studies showed a robust over-expression and hyperphosphorylation of the PKCg
(227.0  15.0% of control) and PKCe (213.9  17.0) isoforms in the rat PAG area. A single oral administration
of SJW produced a significant decrease of the PKCg (131.8  10.0) and PKCe (105.2  12.0) phosphorylation
in the PAG area due to the presence of hypericin. Furthermore, SJW showed a dual mechanism of action since
hyperforin antinociception involves an opioid-dependent pathway. Rats undergoing treatment with SJW and
purified components did not show any behavioural side effects or signs of altered locomotor activity. Our
results indicate SJW as a prolonged antihyperalgesic treatment through inhibition of PKC isoforms and their
phosphorylation.
 2009 Elsevier Inc. All rights reserved.
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Neuropathic pain can arise from a wide variety of injuries to
peripheral or central nerves, including metabolic disorders,
traumatic injury, inflammation, and neurotoxicity, and is charac-
terized by spontaneous pain, hyperalgesia and allodyniawhich can
persist long after the initial injury is resolved [1]. Common causes
of neuropathy are diabetes, herpes zoster infections, chronic or
acute trauma, and neurotoxins. Neuropathic pain occurs frequent-
ly in cancer as it may result from tumor invasion of nervous tissue,
surgical nerve damage during tumor removal, radiation-induced
nerve damage or as a side effect of many chemotherapeutic drugs
[2,3].Abbreviations: CCI, chronic constriction injury; CHL, chloroformic fraction; i.c.v.,
intracerebroventricular; i.p., intraperitoneal; MET, methanolic fraction; OXA,
oxaliplatin repeated administration; p.o., per os; PAG, periaqueductal grey area;
PKC, protein kinase C; PMA, phorbol-12-myristate-13-acetate; SJW, St. John’sWort;
s.c., subcutaneous.
* Corresponding author. Tel.: +39 055 4271312; fax: +39 055 4271280.
E-mail address: nicoletta.galeotti@unifi.it (N. Galeotti).
0006-2952/$ – see front matter  2009 Elsevier Inc. All rights reserved.
doi:10.1016/j.bcp.2009.12.016The underlying molecular mechanisms of neuropathic pain are
still not completely understood, and as a consequence, treatment is
unsatisfactory in many cases [3,4]. Despite the large number of
approved analgesic drugs, effective treatment of chronic pain is still
often unattainable due to the unsatisfactory performance of the
available drugs and due to the negative side effects from the drugs
[5,6].Neuropathicpain is generally insensitive tonon-steroidal anti-
inflammatory drugs and relatively resistant to opioids, but can be
treated by high opioid doses [7] with a high incidence of untoward
side effects. The suggested treatment strategies for neuropathicpain
managementare representedbytricyclicantidepressants (TCAs) [8],
that represent the first medication category proved to be effective
for neuropathic pain in clinical trials [9] and still are a first choice
treatment, anticonvulsants [10,11], antiarrythmics [12]. All these
drugshave limitedefficacyandhavesevere sideeffects. Inparticular,
TCAs induce numerous untoward effects such as sedation,
anticholinergic effects like dry mouth, constipation and postural
hypotension, weight gain, greater risk to develop myocardial
infarction [13,14]. Therefore, for an effective treatment of neuro-
pathic pain, there is still a need to obtain therapeuticswhich possess
a greater level of tolerability and safety.
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(SJW), has been proven to relieve mild-to-moderate forms of
depression and tests have also shown SJW to have favourable side
effects [15]. The most common SJW preparations used are
hydroalcoholic extracts of the aerial portion of the plant that
contain at least ten different kinds of biochemical compounds [16].
SJW interacts with the monoaminergic system through different
mechanisms: the MAO-inhibitory properties of SJW were mainly
due to hypericin [17,18] whereas the inhibition of serotonin,
dopamine and noradrenaline synaptosomal uptake is related to the
presence of hyperforin [19–22]. It has therefore been suggested
that SJWmay induce antidepressant activity through amechanism
similar to TCAs [23]. This evidence may suggest that similar to
TCAs, SJW can also relieve neuropathic pain. The aim of the present
study was to investigate the antihyperalgesic properties of SJW in
different animal models, which were suffering from neuropathic
pain that was induced by chronic constriction injury of the sciatic
nerve, or by the repeated administration of the chemotherapeutic
agent oxaliplatin. The role of the SJWmain constituents, hypericin,
hyperforin and flavonoids, and their cellular and molecular effects
in the modulation of the pain threshold was also investigated in
comparison with the effects produced by the SJW dried extract in
order to better elucidate the mechanism of action in this herbal
plant.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley albino rats (180–200 g) from Harlan (S.
Piero al Natisone, Italy) were used. Four rats were housed per cage.
The cages were placed in the experimental room 24 h before the
test for acclimatization. The animals were fed a standard
laboratory diet and tap water ad libitum and kept at 23  1 8C.
The rats had a 12-h light/dark cycle, light at 7 AM. All experiments
were carried out in accordance with the NIH Guide for the Care and
Use of Laboratory Animals. All efforts were made to minimize animal
suffering, and to reduce the number of animals used.
2.2. Production of neuropathy
2.2.1. Chronic constriction injury
A peripheral mono neuropathy was produced in adult rats by
placing loosely constrictive ligatures around the common sciatic
nerve according to the method described by Bennett and Xie
[24]. Rats were anesthetized with chloral hydrate. The common
sciatic nerve was exposed at the level of the middle of the thigh
by blunt dissection through biceps femoris. Proximal to
sciatica’s trifurcation, about 1 cm of the nerve was freed of
adhering tissue and four ligatures (3/0 chromic tread) were tied
loosely around it with about 1 mm spacing. The length of the
affected nerve was 4–5 mm long. Great care was taken to tie the
ligatures such that the diameter of the nerve was barely
constricted when viewed with 40 magnification. In sham-
operated animals, an identical dissection was performed, but the
sciatic nerve was not ligated. The ligation was made on the right
paws and left paws were untouched. Experiments were carried
out 14 days after surgery.
2.2.2. Oxaliplatin repeated treatment
Oxaliplatin was dissolved in a 5% glucose solution at a
concentration of 2.4 mg kg1. Oxaliplatin was administered i.p.
for five consecutive days per week for three consecutive weeks
according to a previously established protocol [25]. The control
group received a 5% glucose solution. The experiments were
carried out on day 21.2.3. Paw pressure test
The instrument has a cone-shaped pusher and exerts a force
which is applied at a constant rate (32 g per s) on the upper surface
of the rat hind paw. The force is continuously monitored by a
pointer which moves along a linear scale. The pain threshold is
given by the force which first induces struggling from the rat. An
arbitrary cut off value of 250 g was adopted. Those rats scoring
<40 g or over 75 g in the pretest, performed before chronic
constriction injury or oxaliplatin administration, were rejected
(25%). The pain threshold of neuropathic animals was measured
previously (pretest) and then 30, 60, 90, 120 and 180 min after
administration of SJW and components.
2.4. Rota rod test
The apparatus consisted of a base platform and a rotating rod
with a diameter of 3 cm and a non-slippery surface. The rod, 30 cm
in length, was placed at a height of 15 cm from the base. Up to five
rats were tested simultaneously on the apparatus, with a rod-
rotating speed of 16 rpm. The integrity of motor coordination was
assessed on the basis of the number of falls from the rod in 30 s.
Those rats scoring less than three and more than six falls in the
pretestwere rejected (20%). Their performance timewasmeasured
previously (pretest) and then 60, 90 and 120 min after SJW, CHL
and MET fractions or purified components administration. A total
of 4–5 rats per group were tested.
2.5. I.c.v. injection technique
Intracerebroventricular (i.c.v.) administration was performed
under ether anesthesia with isotonic saline as a solvent which has
been previously described [26].
2.6. Preparation of membrane and cytosol fractions
Rat periaqueductal grey (PAG) area was dissected and
homogenized in a homogenizing buffer. The homogenate was
centrifuged at 9000  g for 15 min at 4 8C and the low speed pellet
was discarded. The supernatant (total proteins) was centrifugated
at 100,000  g for 60 min at 4 8C. The resulting supernatant was
the cytosol fraction, and the pellet was resuspended in the
homogenizing buffer containing 0.2% (wt/vol) Triton X-100. The
homogenate was kept at 4 8C for 60 min with occasional stirring
and then centrifugated at 100,000  g for 60 min at 4 8C. The
resulting supernatant was used as the membrane fraction. Protein
concentration of the cytosol and membrane fractions was
quantified using Bradford’s method (protein assay kit, Bio Rad
Laboratories, Milan, Italy).
2.7. Immunoblot analysis
Membrane homogenates (10–50 mg) of naı¨ve, untreated CCI
and SWJ treated CCI rats were separated on 10% SDS-PAGE and
transferred onto nitrocellulose membranes (100 min at 100 V)
using standard procedures. Themembranes were blocked in PBST
(PBS containing 0.1% Tween) containing 5% nonfat dry milk for
90 min. Following washings, blots were incubated overnight at
4 8C with specific antibodies (Santa Cruz Biotechnology, CA, USA)
against PKCg, p-PKCg, PKCe, p-PKCe or b-actin (1:1000 dilution).
After being washed with PBST, the nitrocellulose membranes
were incubated with goat anti-rabbit horseradish peroxidase-
conjugated secondary antisera (1:5000) and left for 90 min at
room temperature. Blotswere then extensivelywashed according
to the manufacturer’s instruction and developed using enhanced
chemiluminescence detection system (Pierce, Milan, Italy). The
Table 1
Composition of the SJW dried extract, CHL and MET fractions.






Rutin, hyperoside, isoquercitrin n.d. 9.29
Quercitrin 0.65 n.d. 0.69
Quercetin 0.83 n.d. 0.42












CHL: chloroform fraction; MET: methanol fraction. The content of each constituent
is expressed as percentage (mg/100mg).
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the blots. Densitometric analysis of scanned images was
performed on a Macintosh iMac computer using the public
domain NIH Image program. Measurements in control samples
were assigned a relative value of 100%. Measurements were
normalised relative to b-actin, used as loading control.
2.8. HPLC-DAD and HPLC–MS drug analyses
To evaluate the content of SJW main components, a HPLC
analysis was performed using a method described in the [27],
modified for our experimental requirements. The identification of
the constituents was performed using combined HPLC-diode array
detection (DAD) analysis and HPLC–thermospray mass spectrom-
etry. The mobile phase was a five-step linear solvent gradient
CH3CN/CH3OH/H2O (pH3.2, HCOOH) over a 60 min period at a flow
rate of 1 ml/min. The quantification of the constituents was
performed using rutin as an external standard and consideration of
each constituent and the relative response factor (RRF) with
respect to the rutin, as previously reported [27].
All the samples were analyzed in triplicate and a calibration
graph with six data points of external standard was used.
2.9. Preparation of chloroform and methanol fractions
A solution of dried SJW extract (1 g) in 10 ml of chloroformwas
stirred for 3 h in the dark. Themixturewas filtered and the solution
was evaporated to obtain a residue of 200 mg, containing the
pholoroglucinols as confirmed by HPLC-DAD–ESI-MS analysis.
The residue present on the filter was washed with 10 ml of
methanol. The methanol solution was evaporated and a residue of
700 mg was obtained. The HPLC-DAD–ESI-MS analysis showed in
this fraction only the presence of flavonoids and naphthodian-
thrones.
2.10. Drugs
Indena Research Laboratories (Settala, Milan, Italy) offered a
commercial sample of Hypericum perforatum dried extract – Lotto
28662/M1 – B.A. 84204 and kindly provided the reference rutin
trihydrate (batch no. K12408717, standard purity 96.25% consid-
ering the content of residual solvents, moisture and amount of
impurities).
The following drugs were used: oxaliplatin (Sequoia Research
Product Ltd., USA), naloxonehydrochloride, hypericin, hyperforin,
hyperoside, quercetin, amentoflavone, amitriptyline hydrochlo-
ride (Sigma, Milan, Italy); phorbol-12-myristate-13-acetate
(PMA), (Calbiochem, Milan, Italy); and carboxymethylcellulose
sodium salt, (CMC) (Fluka Chemie GmbH, Steinheim, Germany).
The other commercially available chemicals used were of the
highest quality.
SJW dried extract, chloroform fraction (CHL), methanol fraction
(MET), hypericin, hyperforin, quercetin, hyperoside and amento-
flavone were dissolved in a 1% CMC solution immediately before
use and administered by oral gavage. Naloxone and amitriptyline
were dissolved in isotonic (NaCl 0.9%) saline solution, PMA was
dissolved in 0.1% DMSO immediately before use. Drug concentra-
tions were prepared to ensure that the necessary dose could be
administered in a volume of 10 ml kg1 by intraperitoneal (i.p.),
per os (p.o.) injection or in a volume of 5ml by i.c.v. injection.
2.11. Drug administration
SJW dried extract, CHL and MET fractions, hypericin, hyper-
forin, quercetin, hyperoside and amentoflavone were adminis-
tered 90 min before the paw pressure test, in correspondence totheir maximum effect as determined by time–course experi-
ments.
TheSJWcomponentswereorally administered90minbefore the
test at the following doses: hypericin 0.06 mg kg1, hyperforin
0.978 mg kg1, quercetin 0.249mg kg1, hyperoside 1.905 mg kg1
and amentoflavone 0.016 mg kg1. These doses correspond to the
amount of each component present in a 30 mg kg1 preparation of
SJW dried extract. CHL and MET fractions were administered in a
concentration containing the above-mentioned content of their
main components, hyperforin and hypericin respectively. The effect
of amitriptyline was evaluated 30 min after administration.
Naloxone (1 mg kg1 i.p.) was injected 70 min after SJW, CHL or
MET administration. PMA (15 pmol per mouse i.c.v.) was injected
30 min after SJW, CHL or MET administration.
The doses and administration schedules of SJW and all other
drugs used were chosen on the bases of time–course and dose–
response experiments previously performed in our laboratory.
2.12. Statistical analysis
All experimental results are given as the mean  s.e.m. An
analysis of variance (ANOVA), followed by Fisher’s Protected Least
Significant Difference procedure for post hoc comparison, were used
to verify significance between two means.
3. Results
3.1. Composition of SJW dried extract, chloroform and methanol
fractions
The main components of SJW dried extract were flavonoids
(12.72%), phloroglucinols (4.23%) and naphthodianthrones (0.32%),
as reported in Table 1. In order to investigate the role of these
components in themechanism of action of SJW, a chloroform and a
methanol fraction were obtained from the dried extract. The
chloroform fraction (CHL) contained phloroglucinols whereas the
methanol fraction (MET) showed the presence of naphthodian-
trones and flavonoids representing a hypericin and flavonoid rich
fraction (Table 1).
Fig. 1. Dose–response curves for the antinociceptive and antihyperalgesic effect of SJW dried extract in the chronic constriction injury of the sciatic nerve (CCI) and repeated
oxaliplatin treatment (OXA) rat model of neuropathic pain. (a) Dose–response curve of SJW dried extract (1–100 mg kg1 p.o.) for the antinociceptive (uninjured leg; SJW
10 mg kg1 p.o, F(1,22) = 6.730, p < 0.05; SJW 30 mg kg1 p.o, F(1,17) = 35.317, p < 0.001) and antihyperalgesic (injured leg; SJW 30 mg kg1 p.o, F(4,44) = 10.690, p < 0.001)
effect in the CCI rats. Datawere recorded 90 min after SJW administration. Experimentswere performed 14 days after surgerywhen a significantmechanical hyperalgesiawas
obtained (F(1,19) = 44.631, p < 0.001). *p < 0.001 in comparison with values recorded before treatment in the corresponding leg; ^p < 0.001 in comparison with the
uninjured leg. (b) Time–course curve of SJW dried extract (30 mg kg1 p.o.) for the antinociceptive activity in naı¨ve rats. *p < 0.01 in comparison with CMC-treated group. (c)
Time–course curve of the mechanical hyperalgesia induced by repeated administration of oxaliplatin in comparison with saline-treated rats. A statistically significant
hyperalgesia appeared on day 21 (F(1,14) = 22.345, p < 0.001); *p < 0.001 compared to saline control group. (d) Dose–response curve of SJW dried extract (10–100 mg kg1
p.o.) for the antinociceptive (saline-treated group; SAL) and antihyperalgesic (OXA; F(4,42) = 12.718, p < 0.001) effect in the rat OXA model of neuropathic pain. Data were
recorded 90 min after SJW administration. *p < 0.001 in comparison with corresponding values recorded before treatment, ^p < 0.001 compared to saline control group. The
experiments were carried out on day 21.
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rat models of neuropathic pain
Two different rat models of neuropathic pain were used:
chronic constriction injury of the sciatic nerve (CCI) and
oxaliplatin repeated administration (OXA). CCI, 14 days after
surgery, inducedmechanical hyperalgesia (rat paw pressure test)
as demonstrated by the reduced pain threshold in the hind paw
affected by CCI in comparisonwith the controlateral uninjured leg
(Fig. 1a F(1,19) = 44.631, p < 0.001). Pain threshold values
comparable to those recorded in the controlateral uninjured leg
were detected in the sham-operated before (65.0  5.5) and after
(64.6  3.3) a single oral administration of CMC. Same results were
obtained in naı¨ve rats (Fig. 1b). Similarly to CCI, oxaliplatin repeated
administration induced the development of neuropathic pain as
illustrated by nociceptive behaviour as compared with the saline-
treated control group. A statistically significant hyperalgesia
appeared on day 21, persisted unmodified up to day 27 and then
it diminished (Fig. 1c).
A single administration of SJW dried extract dose-dependently
(1–100 mg kg1 p.o.) reversed themechanical hyperalgesia in both
models of neuropathic pain: CCI (Fig. 1a) and OXA (Fig. 1d). The
antihyperalgesic effect appeared at antinociceptive doses: the dose
of 1 mg kg1 p.o. was devoid of any effect, at 10 mg kg1 p.o. SJW
significantly increased the rat pain threshold peaking at
30 mg kg1 p.o. At higher concentrations, the antihyperalgesiceffect diminished showing a bell-shaped trend (Fig. 1a and d). The
SJW antihyperalgesic effect was of similar intensity to that
produced by amitriptyline (10 mg kg1 i.p.; 80.3  4.2), used as
reference drug. Time–course experiments showed that the anti-
nociceptive (Fig. 2a and c) and the antihyperalgesic (Fig. 2b and c)
effects of SJW (30 mg kg1 p.o.) share the same profile: they both
became statistically significant 30 min after oral administration,
peaked at 90 min, persisted up to 120 min and disappeared at
180 min in all of the rat models tested for neuropathic pain. In the
sham-operated rats SJW (30 mg kg1 p.o.) increased the pain
threshold (controlateral 110.1  3.1: sham-operated 108.8  5.6)
with similar intensity to that observed in naı¨ve rats (Fig. 1b) and in the
controlateral uninjured leg of CCI rats (Fig. 2a).
The effect produced by a single oral administration of SJWon rat
pain threshold was investigated in the rat paw pressure test.
Administration of drugs by oral gavage can be a stressful procedure
for the animal and currently it is not possible to critically evaluate
the extent towhich some of the drug effects observedmight be due
to stress-induced analgesia associated with handling and injection
of rats. An orally administered vehicle group (CMC) was, therefore,
included in the study. A dried extract of SJW (30 mg kg1 p.o.)
showed antinociceptive activity against a mechanical stimulus in
naı¨ve rats in comparison with CMC-treated animals, used as
control group (Fig. 1b). A single p.o. administration of CMC did not
alter the pain threshold in comparison with the pre-treatment
values (Fig. 1b).
Fig. 2. Time–course curves for the antinociceptive and antihyperalgesic effect of
SJW dried extract in rat models of neuropathic pain induced by chronic constriction
injury of the sciatic nerve (CCI) and repeated administration of oxaliplatin (OXA).
Time–course curves of SJW dried extract (30 mg kg1 p.o.) in the CCI model for the
antinociceptive (uninjured leg) (a) and antihyperalgesic (injured leg) (b) effect.
*p < 0.05 in comparison with CMC-treated group. All data are presented as
mean  s.e.m. (c) Time–course curves of SJW dried extract (30 mg kg1 p.o.) in the
OXAmodel for the antinociceptive (SAL) and antihyperalgesic (OXA) effect. *p < 0.05 in
comparison with SAL before treatment; ^p < 0.05 in comparison with OXA before
treatment. All data are presented as mean  s.e.m. The experiments were carried out
on day 21.
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100 mg kg1 p.o.)mechanical antinociception also in the uninjured
non-hyperalgesic leg of CCI rats. The dose of 1 mg kg1 p.o. was
devoid of any effect (F(1,14) = 2.714, p = 0.121). At 10 mg kg1 p.o.
SJW significantly increased the rat pain threshold. The antinoci-
ceptive effect peaked at 30 mg kg1 p.o. and then it diminished
(Fig. 1a).
SJW was also able to increase the pain threshold in rats treated
for 21 days with a daily injection of saline solution, animals that
represented the control group of the oxaliplatin-treated rats
(Fig. 1d). Time–course experiments confirmed the prolonged effectof SJW in the uninjured leg of CCI rats (Fig. 2a) as well as in the
saline-treated group (Fig. 2c): the antinociception appeared
30 min after a single acute SJW p.o. administration, peaked at
90 min and persisted up to 120 min.
3.3. Analgesic and antihyperalgesic activity of SJW components
The chloroform fraction (CHL), representing a hyperforin rich
fraction, induced antinociception when administered in a concen-
tration corresponding to the content of hyperforin present in a
30 mg kg1 preparation of SJW dried extract. The CHL-induced
increase of the pain threshold was observed in the uninjured leg of
rat with CCI (Fig. 3a) as well as in naı¨ve rats (88.8  4.7). The CHL
antinociceptive dose was also endowed with antihyperalgesic
activity. CHL significantly reversed the hyperalgesia in CCI and
OXA rat models. The effect produced by CHL administration in CCI
rats, taken as example, was reported in Fig. 3a. Conversely, the
methanol fraction (MET), a hypericin/flavonoid rich fraction, selec-
tively induced antihyperalgesia without changing the baseline
mechanical threshold in control rats (lack of antinociceptive
properties). MET, administered in a concentration corresponding to
the content of hypericin present in a 30 mg kg1 preparation of SJW
dried extract, selectively reversed the mechanical hyperalgesia in the
hind paw affected by CCI (Fig. 3b) as well as in the OXAmodel (Fig. 3c)
by increasing the pain threshold up to values comparable to the
control ones. Time–course experiments showed that CHL and MET
were endowed with the same pharmacological profile of the SJW
dried extract (Fig. 3a–c). Purified hyperforin, when administered
alone, produced an antinociceptive/antihyperalgesic effect of inten-
sity comparable to CHL fraction (Fig. 4a). Similarly, purified hypericin
reversed the mechanical hyperalgesia up to a value comparable to
that produced by MET fraction (Fig. 4b). The purified flavonoids
amentoflavone (AME) and hyperoside (HypS) neither showed
antinociceptive/antihyperalgesic properties (Fig. 4c) nor increased
hypericin-induced antihyperalgesia (Fig. 4d). Quercetin (QUER)
produced a significant antihyperalgesic activity even if of lower
intensity than hypericin (Fig. 4c), but it was unable to potentate
hypericin effect (Fig. 4d).
3.4. Mechanism of antinociceptive/antihyperalgesic action of SJW
dried extract and components
SJW dried extract antinociception (30 mg kg1 p.o.) was
prevented by the opioid antagonist naloxone (1 mg kg1 i.p.)
whereas the antihyperalgesic activity was only slightly reduced
(Fig. 5a). The increase of pain threshold as well as the prevention of
the hyperalgesia produced by CHL was completely antagonized by
pre-treatment with the opioid antagonist naloxone (Fig. 5b).
Conversely, the antihyperalgesia induced by MET was naloxone
insensitive (Fig. 5c). The administration of the PKC activator PMA
(15 pmol per mouse i.c.v.) significantly reduced the SJW dried
extract (30 mg kg1 p.o.) antihyperalgesic activity whereas the
antinociception was only slightly reduced (Fig. 6a). PMA selec-
tively prevented the antihyperalgesic effect induced by MET
(Fig. 6b), but was devoid of any effect against the CHL-induced
increase of pain threshold (Fig. 6c). Similar results were obtained
by administering purified hyperforin and hypericin (data not
shown). The opioid antagonist naloxone as well as the PKC
activator PMA, at the concentrations used, were devoid of any
antinociceptive/hypernociceptive effect (71.7  4.7; 72.0  1.7,
respectively). The dose of naloxone of 1 mg kg1 has been demon-
strated to prevent morphine analgesia without modifying the
increase of the pain threshold induced by modification of other
neurotransmission systems (i.e. GABAergic, muscarinic, serotoniner-
gic, etc.). Higher naloxone doses were not employed since lacking of
selectivity toward opioid analgesia.
Fig. 3. Antinociceptive profile of SJW fractions containing the SJW major components in rat models of neuropathic pain. (a) Antinociceptive (uninjured leg; F(3,35) = 5.422,
p < 0.001) and antihyperalgesic (injured leg) effect of the chloroform (CHL) fraction, administered in an amount containing 0.978 mg kg1 hyperforin, in the CCI model. Data
are presented as mean  s.e.m.; *p < 0.001 in comparison with the uninjured leg before treatment; ^p < 0.01 in comparison with the injured leg before treatment. (b)
Antihyperalgesic (injured leg; F(3,32) = 6.002, p < 0.001) effect of the methanol (MET) fraction (30 mg kg1), administered in an amount containing 0.06 mg kg1 hypericin, in the
CCI model. Data are presented as mean  s.e.m.; *p < 0.001 in comparison with uninjured leg before treatment; ^p < 0.05 in comparison with injured leg before treatment. (c) MET
prevented themechanical hyperalgesia induced by oxaliplatin (OXA; F(3,33) = 7.244, p < 0.001) administration without inducing antinociception in the saline (SAL) group. Data are
presented as mean  s.e.m.; *p < 0.001 in comparison with SAL; ^p < 0.001 in comparison with OXA. The experiments were carried out on day 21.
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and PKCe (Fig. 6d) isoforms in the PAG area. This effect was
detected in the total protein preparation (TOT), in the membrane
(MEM) and cytosol (CYT) fractions. A robust increase of the
phosphorylation of PKCg and PKCe was also observed in the totalFig. 4. Antinociceptive profile of purified components of CHL and MET fractions in th
antinociceptive (uninjured leg) and antihyperalgesic (injured leg) properties with a sim
*p < 0.001 in comparison with uninjured leg before treatment; ^p < 0.05 in comparison wit
the mechanical hyperalgesia (injured leg; F(3,35) = 3.992, p < 0.001) without increasing
mean  s.e.m.; *p < 0.001 in comparisonwith uninjured leg before treatment; ^p < 0.001 in
purified flavonoids amentoflavone (AME, 0.016 mg kg1) and hyperoside (HypS, 1.905 m
(F(1,14) = 3.071, p < 0.05). Data are presented as mean  s.e.m.; Data were recorded 90 min
before treatment; ^p < 0.01 in comparison with injured leg before treatment. (d) Amentofl
hypericin-induced antihyperalgesic effect. Data were recorded 90 min after administration
uninjured leg before treatment; ^p < 0.05 in comparison with injured leg before treatmen
component present in a 30 mg kg1 preparation of SJW dried extract.proteins (TOT) (PKCg: F(1,10) = 15.536, p < 0.001; PKCe:
F(1,10) = 18.196, p < 0.001) and in the membrane fraction
(MEM) whereas in the cytosol fraction (CYT) the levels of p-PKCg
and p-PKCe were similar to the control group (Fig. 6d). SJW
treatment was able to reduce the phosphorylation of both PKCe CCI model of neuropathic pain. (a) Purified hyperforin (0.978 mg kg1) showed
ilar profile to CHL (F(3,32) = 4.871, p < 0.001). Data are presented as mean  s.e.m..
h injured leg before treatment. (b) Hypericin (0.06 mg kg1), similarly to MET, reversed
the pain threshold in the non-hyperalgesic (uninjured) leg. Data are presented as
comparison with injured leg before treatment. (c) Lack of effect on pain threshold of the
g kg1). Quercetin (QUER, 0.249 mg kg1) showed a modest antihyperalgesic effect
after administration of SJW constituents. *p < 0.05 in comparison with uninjured leg
avone (AME), hyperoside (HypS) and quercetin (QUER) were unable to potentate the
of SJW constituents. Data are presented as mean  s.e.m. *p < 0.01 in comparison with
t. Each component was administered at a dose corresponding to the amount of each
Fig. 5. Involvement of the opioid system in the antinociceptive activity of SJW and
CHL fraction in the CCI model of neuropathic pain. (a) Prevention by naloxone
(1 mg kg1 i.p.) of SJW dried extract (30 mg kg1 p.o.) antinociception (naı¨ve, sham-
operated, uninjured leg; F(1,18) = 9.487, p < 0.001). Lack of effect on the
antihyperalgesic activity (injured leg; F(1,14) = 2.714, p = 0.121). Data were
recorded 90 min after administration of SJW. Data are presented as
mean  s.e.m.; *p < 0.001 in comparison with uninjured leg before treatment;
^p < 0.01 in comparison with injured leg before treatment. (b) Prevention by
naloxone of CHL (administered in a dose containing 0.978 mg kg1 hyperforin)
antinociception (naı¨ve, sham-operated, uninjured leg; F(1,16) = 8.422, p < 0.001) and
antihyperalgesia (injured leg; F(1,16) = 5.612, p < 0.01). Data were recorded 90 min
after administration of CHL. Data are presented as mean  s.e.m.; *p < 0.05 in
comparisonwith uninjured leg before treatment; ^p < 0.05 in comparisonwith injured
leg before treatment. (c) Lack of effect of naloxone on MET (administered in a dose
containing 0.06 mg kg1 hypericin) antihyperalgesia (injured leg). Data were recorded
90 min after administration of MET. Data are presented as mean  s.e.m.; *p < 0.05 in
comparisonwith uninjured leg before treatment; ^p < 0.05 in comparisonwith injured
leg before treatment.
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levels up to values corresponding to the control (Fig. 6d). Similar
results were obtained in the PAG of OXA rats (data not shown).
Immunoblots were re-probed for a protein considered to be not
regulated as b-actin and no significant density difference was
revealed for this protein among samples.
Cross-reactivity of the primary antibodies used was excluded.
3.5. Effects of SJW dried extract and fractions on rat locomotor
behaviour
The SJWdried extract, CHL andMET fractionswere tested, at the
highest effective doses, in order to assess their effect on rat
locomotor behaviour. Rats pretreated with the above-mentionedextracts at the dose of 30 mg kg1 p.o. were evaluated for motor
coordination by use of the rota rod test. The number of falls from
the rotating rod, evaluated before and 60, 90 and 120 min after
treatments, showed the lack of any impairment in the rat motor
coordination by SJW dried extract and fractions administration in
comparison with the control group (CMC) (Fig. 7a). Each group
progressively reduced its number of falls because mice learned
how to balance on the rotating rod.
Amitriptyline, used as antinociceptive reference drug, at the
dose of 10 mg kg1 did not impair the motor coordination of rats.
Conversely, at a 3 times higher dose (30 mg kg1), it produced an
increase in the number of falls from the rotating rod indicating the
presence of motor incoordination (Fig. 7a). SJW, at a dose of
1000 mg kg1 was still devoid of any side effect (Fig. 7a). Similarly,
purified hypericin, hyperforin, quercetin, hyperoside and amento-
flavone, administered at a concentration corresponding to the
content present in 30 mg kg1 p.o. preparation of SJW dried
extract, were devoid of any effect on the locomotor behaviour
(Fig. 7b).
4. Discussion
We report here the first description of the capability of a SJW
dried extract to reduce hyperalgesia in rat models of neuropathic
pain after a single oral administration.
Painful neuropathy is a condition that may develop when nerve
fibres are damaged or dysfunctional. Since it can arise from a wide
variety of injuries, two different models of neuropathic pain were
used. The chronic constriction injury of the sciatic nerve was used
as a model of neuropathy being induced by nerve damage whereas
the repeated administration of oxaliplatin represented a chemo-
therapy-induced neuropathic pain model. A single oral adminis-
tration of SJW reversed mechanical hyperalgesia in both models of
neuropathic pain producing a prolonged increase of the pain
threshold that continued up to 120 min. The efficacy of SJW in the
management of neuropathic pain, regardless of the kind of injury
responsible for the painful condition, was suggested. A clinical
study conducted in patients suffering frompainful polyneuropathy
reported a trend of lower pain scores when treated with SJW than
did the patients who were treated with a placebo. A statistically
significant relief of pain was not obtained [28], and this
discrepancy might be explained by considering that the SJW-
induced antinociception has a bell-shaped trend. The authors
looked for an increase of the pain threshold at a concentration
(2.7 mg/die total hypericins) similar to that which was employed
in trials with depressed patients. This concentration was about 30
times higher than the analgesic concentration (0.096 mg total
hypericins) and, as demonstrated by dose–response experiments,
at this level the antinociceptive efficacy of SJW is strongly reduced.
At doses able to reverse hyperalgesia, SJW-induced mechanical
antinociception in untreated non-painful rats (control groups) as
well as in the controlateral uninjured hind limbs of CCI rats. These
reports confirm and support the hypothesis for the role that SJW
has in themodulation of pain perception. This hypothesis has been
suggested in a recent paper that indicates the antinociceptive
properties of SJW in the mouse formalin test [29].
The main components of the SJW dried extract are phloroglu-
cinols, naphthodiantrones and flavonoids. The effects produced by
these constituents were investigated in order to discover the
components responsible for the antinociceptive activity and to
better elucidate the SJW mechanism of analgesic action. We
obtained a chloroform fraction (CHL) containing phloroglucinols,
mainly represented by hyperforin, and a methanol fraction (MET)
that was a hypericin and flavonoid rich fraction. CHL fraction
reversed the mechanical hyperalgesia in all neuropathic pain
models and increased the pain threshold in the control non-painful
Fig. 6. Blockade of the PKC activity asmechanism of the antihyperalgesic effect of SJWandMET fraction in the CCImodel of neuropathic pain. (a) The administration of the PKC
activator PMA (15 pmol per mouse i.c.v.) significantly reduced the SJW dried extract (30 mg kg1 p.o.) antihyperalgesic activity (F(1,14) = 5.729, p < 0.001) whereas the
antinociception was only slightly reduced (F(1,14) = 2.714, p = 0.0487). Data were recorded 90 min after administration of SJW. (b) Prevention by the PKC activator PMA of
MET antihyperalgesic activity (injured leg; F(1,15) = 6.231, p < 0.001). Data were recorded 90 min after administration of MET. (c) Lack of effect of PMA on the CHL-induced
antinociception (uninjured leg) and antihyperalgesia (injured leg). Data were recorded 90 min after administration of CHL. Data are presented as mean  s.e.m.; *p < 0.001 in
comparison with uninjured leg; ^p < 0.01 in comparison with injured leg. (d) The CCI induced an increase in the PKCg and PKCe isoforms levels observed in the total protein
preparation (TOT; PKCg: F(1,10) = 3.991, p < 0.01; PKCe: F(1,10) = 4.961, p < 0.01) and in themembrane (MEM) and cytosol (CYT) fractions from the periaqueductal grey (PAG) area
of neuropathic rats. A dramatic increase of the phosphorylation of PKCg and PKCewas observed in the total protein preparation (TOT) andmembrane (MEM) fractionwhereas in the
cytosol (CYT) fraction no variation was detected. SJW decreased the phosphorylation of PKCg and PKCe isoforms up to control values. Densitometric values are reported as
percentage of control. *p < 0.01 in comparison with control group; §p < 0.05 in comparison with CCI.
N. Galeotti et al. / Biochemical Pharmacology 79 (2010) 1327–13361334animals. The intensity of the CHL fraction activity was lower than
that of the SJW dried extract, but a similar time–course profile was
observed. The MET fraction was as effective as the CHL in relieving
neuropathic pain. This indicates that the SJW main components
present in both fractions are responsible for the antihyperalgesic
properties of the plant. It is interesting to note thatMET, conversely
to CHL, was devoid of any analgesic activity in the non-painful rats.
These results might suggest a selective role of hypericin/flavonoid
in the relief of neuropathic pain, rather than being effective as a
direct result of their antinociceptive properties.The SJW antinociception underlies the activation of the opioid
system as this analgesia is prevented by the opioid antagonist
naloxone. Binding of [3H]naloxone to them- and k-opioid receptor
was inhibited in the presence of SJW extract [30], further
supporting a SJW opioid mechanism. Phloroglucinols might be
responsible for this opioid effect since hyperforin inhibited binding
to the opioid receptors with a higher affinity than hypericin and
flavonoids [30,31]. The prevention by naloxone of CHL-induced
antinociception further supports this hypothesis. CHL fraction
contains phloroglucinols together with a small amount of the
Fig. 7. Lack of induction of locomotor side effects by SJW dried extract, fractions and purified components. (a) Lack of effect of SJW dried extract, CHL andMET fractions on rat
motor coordination evaluated in the rat rota rod test. Effects produced by amitriptyline (AMI) at the doses of 10 and 30 mg kg1, used as reference antinociceptive drug.
*p < 0.05 in comparison with CMC-treated rats. (b) Purified SJW main components showed the lack of any influence on locomotor behaviour. A total of 4–5 rats per group
were tested.
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lower affinity than hyperforin [31]. The administration of purified
hyperforin produced an antinociceptive effect comparable to that
induced by the CHL fraction, which further suggests the prominent
role of hyperforin in the CHL activity.
The MET fraction contains hypericins and flavonoids, both of
which might be potentially involved in the SJW mechanism of
antinociceptive action. The total amount of hypericins add up to
about 0.3% of the SJW dried extract and have long been known to
be related to many pharmacological properties of SJW. Recent
studies report antidepressive, antineoplastic, antitumor and
antiviral activities of hypericin [18]. Flavonoids contribute to the
anti-inflammatory effects of the plant [32] and antinociceptive
properties have been reported for the flavonoid myricitrin [33].
Enzyme assays performed on rat brains demonstrated that
hypericin and pseudohypericin are potent and selective inhibitors
of the protein kinase C (PKC) [34,18]. In vitro studies reported that
some flavonoids inhibit rat brain PKC activity. Among the
flavonoids, quercetin is one of the most significant [35]. PKC is a
family of enzymes involved in numerous important cellular events,
including pain modulation. PKC integrates numerous receptor
pathways into final effectors that increase excitatory signalling and
decrease inhibitory signalling, thus inducing pain. The activation of
PKC has been related to the induction of a painful condition
whereas PKC blockers decreased nociception [36]. Pre-treatment
with the PKC activator PMA antagonized the MET-induced
antinociception, whereas with the CHL-induced, the increase of
the pain threshold remained unmodified. Conversely to the CHL
fraction, the MET fractions mechanical antihyperalgesia remains
unmodified by the naloxone pre-treatment. These results suggest
that a selective blockade of the PKC-mediated intracellular
pathway underlies the MET activity.
PKC is a family of serine/threonine kinases that are divided into
three groups based on calcium and diacylglycerol dependence:
conventional (a,bI,bII, andg), novel (d, e,h, andu), atypical (z and
l/i) [37]. Among them, PKCe and PKCg isoforms appear to play a
prominent role in the modulation of pain perception [36,38,39]. In
particular, the translocation of these enzymes from the cytosol to
the synaptic membrane is thought to be necessary for their
activation [40]. Increased translocation and activation of PKC in
dorsal horn neurons has been shown in a number of pain models.This suggests the importance in the modulation of pain perception
of spinally located PKC [36]. We have detected a specific
upregulation of PKCg and PKCe isoforms in the PAG area of
neuropathic rats alongwith a robust increase of the PKCg and PKCe
phosphorylation. Furthermore, we discovered a lack of increase in
any of the phosphorylation of PKCe and PKCg in the cytosol in
comparison with the high phosphorylated form levels observed in
the membrane fraction of neuropathic rats. These results have
highlighted the importance of supraspinally located PKC in the
modulation of the sensation of pain. This suggests that in the
presence of neuropathies, the activation of the PKC-mediated
pathway is not only confined to the spinal cord. The SJW oral
administration produced a complete reversal of the phosphoryla-
tion of both PKCe and PKCg in the total protein preparation as well
as in themembrane fraction. These data suggest the hypothesis of a
PKC-inhibitingmechanism in SJW for antinociception and indicate
the isoforms e and g of PKC as potential targets for this
antinociceptive effect. Furthermore, the importance of the inhibi-
tion of the PKC activity in order to treat neuropathic pain is further
confirmed.
To identify the MET component responsible for the increase of
pain threshold, the effect produced by administration of purified
MET fraction components was investigated. Hypericin showed
antinociceptive properties of intensity comparable to that
produced by the MET fraction. Conversely, hyperoside, which is
the most abundant flavonoid present in the SJW dried extract,
neither increased the pain threshold nor potentated the hypericin-
induced antinociception. Anti-inflammatory properties were
reported for the flavonoid amentoflavone [41], but, when
administered alone in neuropathic rats, it was devoid of any
antinociceptive effect. Quercetin was unable to potentate hyper-
icin antinociception when co-administered, even if it resulted in
being slightly effective in increasing the pain threshold. This is not
surprising since quercetin, which is similar to hypericin, has PKC-
blocking properties. A quercetin potency about 30 times lower [35]
than hypericin [34] might explain the lower efficacy observed in
behavioural tests. Hypericin appears, therefore, to be the most
effective component of the MET fraction.
An important drawback of the current analgesic therapy of
neuropathic pain is the high occurrence of side effects [42]. The
potential induction of side effects by SJW and components at the
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investigated. In accordance with the literature data that indicate
SJW as a medicinal plant with a favourable tolerability and safety
profile [15], the SJW dried extract, CHL and MET fractions, at the
highest active doses employed in the present study, caused neither
detectable modification in the rats gross behaviour, nor did they
alter their locomotive activity. Similar profile was also demon-
strated by purified SJW main components.
In conclusion, our findings showed that a single oral
administration of SJW, CHL and MET fractions, as well as
purified hyperforin and hypericin, relieve neuropathic pain in
rats with a very positive side-effects profile. This increase of the
pain threshold is related to the modulation of two different
intracellular pathways: the activation of the opioid system,
underling the presence of hyperforin, which is responsible for
the antinociceptive properties, and a PKC-mediated mechanism
through the PKC-blocking properties of hypericin, mainly
related to the antihyperalgesic activity. Finally, these results
further support the hypothesis that the inhibition of PKC specific
isoforms might be a promising strategy for effective treatment
of neuropathic pain.
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